Tyra Biosciences, Inc.
TYRA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001863127
In the last 90 days, Tyra Biosciences, Inc. insiders filed 1 open-market purchase and 0 sales; 168 institutions reported holding it in 13F filings for Q2 2026, worth $2.22B in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 11, 2026, 1:17 AM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 2, 2026 | Mar 27, 2025 | Mar 19, 2024 | Mar 22, 2023 | Mar 3, 2022 |
| Operating expenses | $132.8M | $104.2M | $79.9M | $58.9M | $26.3M |
| Research and development | $102.9M | $80.1M | $62.5M | $43.0M | $20.6M |
| Selling, general and administrative | $29.8M | $24.1M | $17.4M | $15.9M | $5.65M |
| Operating income | -$132.8M | -$104.2M | -$79.9M | -$58.9M | -$26.3M |
| Income tax | $0 | $0 | $0 | $2.00K | $1.00K |
| Net income | -$119.9M | -$86.5M | -$69.1M | -$55.3M | -$26.3M |
| EPS, basic | $-2.01 | $-1.51 | $-1.62 | $-1.32 | – |
| EPS, diluted | $-2.01 | $-1.51 | $-1.62 | $-1.32 | – |
| Weighted shares, basic | 59.6M | 57.2M | 42.7M | 41.9M | – |
| Weighted shares, diluted | 59.6M | 57.2M | 42.7M | 41.9M | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 2, 2026 | Mar 27, 2025 | Mar 19, 2024 | Mar 22, 2023 | Mar 3, 2022 |
| Cash and equivalents | $77.4M | $92.0M | $58.0M | $251.2M | $302.2M |
| Total current assets | $265.4M | $347.5M | $211.7M | $257.3M | $304.1M |
| Property, plant and equipment | $1.31M | $1.65M | $1.63M | $1.08M | $1.03M |
| Total assets | $282.6M | $363.6M | $225.9M | $266.2M | $306.7M |
| Accounts payable | $1.18M | $590.0K | $4.66M | $1.15M | $599.0K |
| Total current liabilities | $18.1M | $14.6M | $15.3M | $5.70M | $3.62M |
| Total liabilities | $23.4M | $20.4M | $21.6M | $8.35M | $4.96M |
| Shareholders' equity | $259.2M | $343.2M | $204.3M | $257.8M | $301.7M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 2, 2026 | Mar 27, 2025 | Mar 19, 2024 | Mar 22, 2023 | Mar 3, 2022 |
| Operating cash flow | -$95.1M | -$69.8M | -$50.1M | -$50.3M | -$23.7M |
| Capital expenditures | $141.0K | $664.0K | $770.0K | $559.0K | $661.0K |
| Free cash flow | -$95.3M | -$70.4M | -$50.9M | -$50.8M | -$24.4M |
| Depreciation and amortization | $546.0K | $519.0K | $353.0K | $296.0K | $140.0K |
| Stock-based compensation | $28.0M | $22.8M | $13.5M | $10.6M | $2.89M |
| Investing cash flow | $72.5M | -$98.4M | -$144.6M | -$559.0K | -$645.0K |
| Financing cash flow | $8.10M | $202.1M | $1.54M | $632.0K | $311.3M |
| Net change in cash | -$14.6M | $34.0M | -$193.2M | -$50.2M | $287.0M |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 6, 2026 | 69.1M | +29.4% | SEC |
| Jul 31, 2026 | 59.7M | +12.0% | SEC |
| May 8, 2026 | 59.5M | +11.8% | SEC |
| Feb 25, 2026 | 53.9M | +1.5% | SEC |
| Oct 31, 2025 | 53.4M | +5.5% | SEC |
| Aug 11, 2025 | 53.3M | +0.9% | SEC |
| May 5, 2025 | 53.2M | +1.2% | SEC |
| Mar 25, 2025 | 53.1M | +1.1% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.